Director/PDMR Shareholding

    Director/PDMR Shareholding

DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 30 April 2024 Mr Bob Sutcliffe, tha Chairman, purchased a total of 100,000 Ordinary Shares in the Company at a price of 1.46p per share.

Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 933,386 Ordinary Shares representing 1.46% of the issued share capital of the Company.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robert Sutcliffe
2	Reason for the notification
a)	Position/status	Chairman
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	DXS INTERNATIONAL PLC
b)	LEI	2138001R1KEUWTXEVJ44
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.33p each
	Identification code	ISIN GB00B2Q6HZ92
b)	Nature of the transaction	Issue of new shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1.46p	100,000
d)	Aggregated information
	- Aggregated volume
	- Price
e)	Date of the transaction	30 April 2024
f)	Place of the transaction	Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Enquiries:

David Immelman      (Chief Executive) DXS International plc	01252 719800 [e-mail]
Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS
www.dxs-systems.co.uk

Corporate Advisor
David Papworth City & Merchant	0207 101 7676

Corporate Broker
Hybridan LLP Claire Louise Noyce	020 3764 2341

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.